Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market: By Treatment Type: Stimulants, Non-Stimulants; By Age Group: Adult, Children; By Gender: Male, Female; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others; Regional Analysis; Market Dynamics: SWOT Analysis, PESTEL Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Overview – 8 Major Markets 
    3.1    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2017-2023) 
    3.2    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2024-2032) 
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Attention  Deficit Hyperactivity Disorder (ADHD) Treatment Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Treatment Pathway 
6    Patient Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Treatment Success Rate
7    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market - Epidemiology Scenario and Forecast – 8 Major Markets
    7.1    8MM Epidemiology Scenario Overview (2017-2032)
        7.1.1    Prevalence, by Country
            7.1.1.1    United States 
            7.1.1.2    United Kingdom
            7.1.1.3    EU4
            7.1.1.4    India
            7.1.1.5    Japan
        7.1.2    Diagnosed Cases, by Country
            7.1.2.1    United States 
            7.1.2.2    United Kingdom
            7.1.2.3    EU4
            7.1.2.4    India
            7.1.2.5    Japan
        7.1.3    Treatment seeking rate, by Country 
            7.1.3.1    United States 
            7.1.3.2    United Kingdom
            7.1.3.3    EU4
            7.1.3.4    India
            7.1.3.5    Japan
8    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Landscape – 8 Major Markets 
    8.1    Attention Deficit Hyperactivity Disorder (ADHD) Treatment: Developers Landscape
        8.1.1    Analysis by Year of Establishment
        8.1.2    Analysis by Company Size
        8.1.3    Analysis by Region
    8.2    Attention Deficit Hyperactivity Disorder (ADHD) Treatment: Product Landscape
        8.2.1    Analysis by Treatment Type 
        8.2.2    Analysis by Age Group 
        8.2.3    Analysis by Route of Administration
9    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Challenges and Unmet Needs
    9.1    Treatment Pathway Challenges
    9.2    Compliance and Drop-Out Analysis
    9.3    Awareness and Prevention Gaps
10    Cost of Treatment
11    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Dynamics
    11.1    Market Drivers and Constraints
    11.2    SWOT Analysis
        11.2.1    Strengths
        11.2.2    Weaknesses
        11.2.3    Opportunities
        11.2.4    Threats
    11.3    PESTEL Analysis
        11.3.1    Political
        11.3.2    Economic
        11.3.3    Social
        11.3.4    Technological
        11.3.5    Legal
        11.3.6    Environment
    11.4    Porter’s Five Forces Model
        11.4.1    Bargaining Power of Suppliers
        11.4.2    Bargaining Power of Buyers
        11.4.3    Threat of New Entrants
        11.4.4    Threat of Substitutes
        11.4.5    Degree of Rivalry
    11.5    Key Demand Indicators 
    11.6    Key Price Indicators
    11.7    Industry Events, Initiatives, and Trends  
    11.8    Value Chain Analysis
12    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Segmentation (2017-2032) - 8 Major Markets 
    12.1    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment Type
        12.1.1    Market Overview
        12.1.2    Stimulants
            12.1.2.1    Amphetamine
            12.1.2.2    Methylphenidate
            12.1.2.3    Dextroamphetamine
            12.1.2.4    Dexmethylphenidate
            12.1.2.5    Lisdexamfetamine Dimesylate
        12.1.3    Non-Stimulants
            12.1.3.1    Atomoxetine
            12.1.3.2    Bupropion
            12.1.3.3    Guanfacine
            12.1.3.4    Clonidine
    12.2    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
        12.2.1    Market Overview
        12.2.2    Adult
        12.2.3    Children
    12.3    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
        12.3.1    Market Overview
        12.3.2    Male
        12.3.3    Female 
    12.4    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
        12.4.1    Market Overview
        12.4.2    Hospital Pharmacies
        12.4.3    Retail Pharmacies
        12.4.4    Others
    12.5    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Region
        12.5.1    Market Overview
        12.5.2    United States
        12.5.3    EU-4 and the United Kingdom
            12.5.3.1    Germany
            12.5.3.2    France
            12.5.3.3    Italy
            12.5.3.4    Spain
            12.5.3.5    United Kingdom
        12.5.4    Japan
        12.5.5    India 
13    United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032)
    13.1    United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2017-2023) 
    13.2    United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2024-2032)
    13.3    United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment T ype
        13.3.1    Market Overview
        13.3.2    Stimulants
            13.3.2.1    Amphetamine
            13.3.2.2    Methylphenidate
            13.3.2.3    Dextroamphetamine
            13.3.2.4    Dexmethylphenidate
            13.3.2.5    Lisdexamfetamine Dimesylate
        13.3.3    Non-Stimulants 
            13.3.3.1    Atomoxetine
            13.3.3.2    Bupropion
            13.3.3.3    Guanfacine
            13.3.3.4    Clonidine
    13.4    United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
        13.4.1    Market Overview
        13.4.2    Adult
        13.4.3    Children
    13.5    United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
        13.5.1    Market Overview
        13.5.2    Male
        13.5.3    Female 
    13.6    United States Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
        13.6.1    Market Overview
        13.6.2    Hospital Pharmacies
        13.6.3    Retail Pharmacies
        13.6.4    Others
14    EU-4 and United  Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032)
    14.1    EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2017-2023) 
    14.2    EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2024-2032)
    14.3    EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment Type
        14.3.1    Market Overview
        14.3.2    Stimulants
            14.3.2.1    Amphetamine
            14.3.2.2    Methylphenidate
            14.3.2.3    Dextroamphetamine
            14.3.2.4    Dexmethylphenidate
            14.3.2.5    Lisdexamfetamine Dimesylate
        14.3.3    Non- Stimulants
            14.3.3.1    Atomoxetine
            14.3.3.2    Bupropion
            14.3.3.3    Guanfacine
            14.3.3.4    Clonidine
    14.4    EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
        14.4.1    Market Overview
        14.4.2    Adult
        14.4.3    Children
    14.5    EU-4 and United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
        14.5.1    Market Overview
        14.5.2    Male
        14.5.3    Female 
    14.6    EU-4 and United Kingdom ttention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
        14.6.1    Market Overview
        14.6.2    Hospital Pharmacies
        14.6.3    Retail Pharmacies
        14.6.4    Others
15    Japan Attention  Deficit Hyperactivity Disorder (ADHD) Treatment Market
    15.1    Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2017-2023) 
    15.2    Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2024-2032)
    15.3    Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment T ype
        15.3.1    Market Overview
        15.3.2    Stimulants
            15.3.2.1    Amphetamine
            15.3.2.2    Methylphenidate
            15.3.2.3    Dextroamphetamine
            15.3.2.4    Dexmethylphenidate
            15.3.2.5    Lisdexamfetamine Dimesylate
        15.3.3    Non-Stimulants 
            15.3.3.1    Atomoxetine
            15.3.3.2    Bupropion
            15.3.3.3    Guanfacine
            15.3.3.4    Clonidine
    15.4    Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
        15.4.1    Market Overview
        15.4.2    Adult
        15.4.3    Children
    15.5    Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
        15.5.1    Market Overview
        15.5.2    Male
        15.5.3    Female 
    15.6    Japan Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
        15.6.1    Market Overview
        15.6.2    Hospital Pharmacies
        15.6.3    Retail Pharmacies
        15.6.4    Others
16    India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
    16.1    India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) Historical Value (2017-2023) 
    16.2    India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) Forecast Value (2024-2032)
    16.3    India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Treatment T ype
        16.3.1    Market Overview
        16.3.2    Stimulants
            16.3.2.1    Amphetamine
            16.3.2.2    Methylphenidate
            16.3.2.3    Dextroamphetamine
            16.3.2.4    Dexmethylphenidate
            16.3.2.5    Lisdexamfetamine Dimesylate
        16.3.3    Non-Stimulants 
            16.3.3.1    Atomoxetine
            16.3.3.2    Bupropion
            16.3.3.3    Guanfacine
            16.3.3.4    Clonidine
    16.4    India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Age Group
        16.4.1    Market Overview
        16.4.2    Adult
        16.4.3    Children
    16.5    India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Gender
        16.5.1    Market Overview
        16.5.2    Male
        16.5.3    Female 
    16.6    India Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market (2017-2032) by Distribution Channel
        16.6.1    Market Overview
        16.6.2    Hospital Pharmacies
        16.6.3    Retail Pharmacies
        16.6.4    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    Japan PMDA
        17.1.4    India CDSCO
        17.1.5    Others
18    Clinical Trials Analysis
    18.1    Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Grants Analysis
    19.1    Analysis by Year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Funding and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Strategic Initiatives
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    Market Share by Top 5 Companies
    22.2    Takeda Pharmaceutical Company Limited
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Company News and Development
        22.2.5    Certifications
    22.3    Aytu BioPharma, Inc.
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Company News and Development
        22.3.5    Certifications
    22.4    Eli Lilly and Company
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Company News and Development
        22.4.5    Certifications
    22.5    Pfizer Inc. 
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Company News and Development
        22.5.5    Certifications
    22.6    Noven Pharmaceuticals Inc. 
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Company News and Development
        22.6.5    Certifications
    22.7    Supernus Pharmaceuticals, Inc.
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Company News and Development
        22.7.5    Certifications
    22.8    Johnson & Johnson Servi ces Inc.
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Company News and Development
        22.8.5    Certifications
    22.9    Novartis A G
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Company News and Development
        22.9.5    Certifications
    22.10    Curemark, LLC 
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Company News and Development
        22.10.5    Certifications
    22.11    GlaxoSmithKline Plc 
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Company News and Development
        22.11.5    Certifications
    22.12    Highland Therapeutics Inc.
        22.12.1    Financial Analysis
        22.12.2    Product Portfolio
        22.12.3    Demographic Reach and Achievements
        22.12.4    Company News and Development
        22.12.5    Certifications
23    Attention Deficit Hyperactivity Disorder (ADHD) Treatment Treatment Drugs - Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.